Prostate cancer patients could soon be in for potentially good news after clinical stage-drug development company, Noxopharm (ASX: NOX) reported…
Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial…